Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A dominant EV71-specific CD4+ T cell epitope is highly conserved among human enteroviruses.

Wei R, Yang C, Zeng M, Terry F, Zhu K, Yang C, Altmeyer R, Martin W, De Groot AS, Leng Q.

PLoS One. 2012;7(12):e51957. doi: 10.1371/journal.pone.0051957. Epub 2012 Dec 14. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/434cdaa5-9654-4052-b325-fef0f31d4657.

2.

VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population.

Tan S, Tan X, Sun X, Lu G, Chen CC, Yan J, Liu J, Xu W, Gao GF.

J Immunol. 2013 Aug 15;191(4):1637-47. doi: 10.4049/jimmunol.1301439. Epub 2013 Jul 17.

3.

Dominant CD4-dependent RNA-dependent RNA polymerase-specific T-cell responses in children acutely infected with human enterovirus 71 and healthy adult controls.

Dang S, Gao N, Li Y, Li M, Wang X, Jia X, Zhai S, Zhang X, Liu J, Deng H, Dong T.

Immunology. 2014 May;142(1):89-100. doi: 10.1111/imm.12235.

4.

Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine.

Han X, Ying XL, Zhou SL, Han T, Huang H, Jin Q, Yang F, Sun QY, Sun XX.

Hum Vaccin Immunother. 2014;10(8):2220-6. doi: 10.4161/hv.29123.

5.

A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice.

Yang L, Liu Y, Li S, Zhao H, Lin Q, Yu H, Huang X, Zheng Q, Cheng T, Xia N.

Vaccine. 2016 Nov 21;34(48):5938-5945. doi: 10.1016/j.vaccine.2016.10.018. Epub 2016 Oct 19.

PMID:
27771182
6.

Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein.

Kiener TK, Jia Q, Lim XF, He F, Meng T, Chow VT, Kwang J.

Virol J. 2012 Feb 24;9:55. doi: 10.1186/1743-422X-9-55.

7.

The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.

Mao Q, Wang Y, Shao J, Ying Z, Gao F, Yao X, Li C, Ye Q, Xu M, Li R, Zhu F, Liang Z.

Hum Vaccin Immunother. 2015;11(11):2723-33. doi: 10.1080/21645515.2015.1011975. Epub 2015 Feb 25.

8.

Identification and characterization of a cross-neutralization epitope of Enterovirus 71.

Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, Sia C, Chong P.

Vaccine. 2011 Jun 10;29(26):4362-72. doi: 10.1016/j.vaccine.2011.04.010. Epub 2011 Apr 16.

PMID:
21501643
9.

Characterization of the antibody response against EV71 capsid proteins in Chinese individuals by NEIBM-ELISA.

Ding Y, Chen X, Qian B, Wu G, He T, Feng J, Gao C, Wang L, Wang J, Li X, Cao M, Peng H, Zhao C, Pan W.

Sci Rep. 2015 May 29;5:10636. doi: 10.1038/srep10636.

10.

Enterovirus 71 vaccine: close but still far.

Zhang D, Lu J, Lu J.

Int J Infect Dis. 2010 Sep;14(9):e739-43. doi: 10.1016/j.ijid.2009.12.002. Epub 2010 Apr 18. Review.

11.

Enterovirus-Specific Anti-peptide Antibodies.

Poh CL, Kirk K, Chua HN, Grollo L.

Methods Mol Biol. 2015;1348:341-50. doi: 10.1007/978-1-4939-2999-3_29.

PMID:
26424285
12.

Challenges to licensure of enterovirus 71 vaccines.

Lee MS, Tseng FC, Wang JR, Chi CY, Chong P, Su IJ.

PLoS Negl Trop Dis. 2012;6(8):e1737. doi: 10.1371/journal.pntd.0001737. Epub 2012 Aug 28. Review.

13.

Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop.

Xu L, He D, Li Z, Zheng J, Yang L, Yu M, Yu H, Chen Y, Que Y, Shih JW, Liu G, Zhang J, Zhao Q, Cheng T, Xia N.

Theranostics. 2014 Feb 18;4(5):498-513. doi: 10.7150/thno.7457. eCollection 2014.

14.

Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease.

Tsou YL, Lin YW, Shao HY, Yu SL, Wu SR, Lin HY, Liu CC, Huang C, Chong P, Chow YH.

PLoS Negl Trop Dis. 2015 Apr 9;9(4):e0003692. doi: 10.1371/journal.pntd.0003692. eCollection 2015 Apr.

15.

CD4 T-cell-independent antibody response reduces enterovirus 71 lethality in mice by decreasing tissue viral loads.

Wang LC, Kao CM, Ling P, Su IJ, Chang TM, Chen SH.

Clin Dev Immunol. 2012;2012:580696. doi: 10.1155/2012/580696. Epub 2012 Oct 24.

17.

An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice.

In HJ, Lim H, Lee JA, Kim HJ, Kim JW, Hyeon JY, Yeo SG, Lee JW, Yoo JS, Choi YK, Lee SW.

PLoS One. 2017 May 24;12(5):e0178259. doi: 10.1371/journal.pone.0178259. eCollection 2017.

18.
19.

Elevated antigen-specific Th2 type response is associated with the poor prognosis of hand, foot and mouth disease.

Wei R, Xu L, Zhang N, Zhu K, Yang J, Yang C, Deng C, Zhu Z, De Groot AS, Altmeyer R, Zeng M, Leng Q.

Virus Res. 2013 Oct;177(1):62-5. doi: 10.1016/j.virusres.2013.07.009. Epub 2013 Jul 22.

PMID:
23886670
20.

Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.

Sun S, Jiang L, Liang Z, Mao Q, Su W, Zhang H, Li X, Jin J, Xu L, Zhao D, Fan P, An D, Yang P, Lu J, Lv X, Sun B, Xu F, Kong W, Jiang C.

Hum Vaccin Immunother. 2014;10(10):2885-95. doi: 10.4161/hv.29823.

Supplemental Content

Support Center